Last reviewed · How we verify
isoniazid, rifampin, pyrazinamide
isoniazid, rifampin, pyrazinamide is a Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved. Also known as: INH, RIF, PZA.
Isoniazid, rifampin, and pyrazinamide, marketed by National Taiwan University Hospital, are established treatments for tuberculosis. The key composition patent expires in 2028, providing a period of market exclusivity and potential revenue stability. The primary risk is the lack of reported key trial results and revenue data, which may limit investor confidence and market valuation.
At a glance
| Generic name | isoniazid, rifampin, pyrazinamide |
|---|---|
| Also known as | INH, RIF, PZA |
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Shortened Regimen for Drug-susceptible TB in Children (PHASE3)
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (PHASE2)
- Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis (PHASE2)
- Digitally Facilitated, Integrated Community and Facility-Based Interventions: The HEART-TB Trial Protocol (NA)
- Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB (PHASE2)
- Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- isoniazid, rifampin, pyrazinamide CI brief — competitive landscape report
- isoniazid, rifampin, pyrazinamide updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI
Frequently asked questions about isoniazid, rifampin, pyrazinamide
What is isoniazid, rifampin, pyrazinamide?
Who makes isoniazid, rifampin, pyrazinamide?
Is isoniazid, rifampin, pyrazinamide also known as anything else?
What development phase is isoniazid, rifampin, pyrazinamide in?
Related
- Manufacturer: National Taiwan University Hospital — full pipeline
- Also known as: INH, RIF, PZA
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing